LONAFARNIB FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

The invention pertains to the use of lonafarnib or any analog or derivative thereof for the treatment of a viral disease characterized by a viral entry into a host cell via a viral fusion glycoprotein (F-protein). In particular, the invention provides treatments of human respiratory syncytial virus...

Full description

Saved in:
Bibliographic Details
Main Authors HAID, Sibylle, SCHULZ, Thomas, PIETSCHMANN, Thomas, SAKE, Svenja, RÜCKERT, Jessica
Format Patent
LanguageEnglish
French
German
Published 29.11.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention pertains to the use of lonafarnib or any analog or derivative thereof for the treatment of a viral disease characterized by a viral entry into a host cell via a viral fusion glycoprotein (F-protein). In particular, the invention provides treatments of human respiratory syncytial virus (HRSV) caused diseases comprising the administration (use) of lonafarnib or its analogs or derivatives, as well as pharmaceutical compositions comprising lonafarnib or its analogs and derivates.
Bibliography:Application Number: EP20220702217